25 MJ 504
Generic Name: cyclophosphamide
Pill imprint 25 MJ 504 has been identified as Cytoxan 25 mg.
Cytoxan is used in the treatment of cancer; brain tumor; cervical cancer; breast cancer; ovarian cancer (and more), and belongs to the drug class alkylating agents. There is positive evidence of human fetal risk during pregnancy.
Cytoxan 25 mg is not subject to the Controlled Substances Act.
See also related documents.
Cytoxan Images
- Generic Name:
- cyclophosphamide
- Imprint:
-
25
MJ 504 - Strength:
- 25 mg
- Color:
- White & Blue Specks
- Size:
- 9.00 mm
- Shape:
- Round
- Availability:
- Prescription only
- Inactive Ingredients:
- acacia
FD&C Blue No. 1
aluminum oxide
D&C Yellow No. 10
lactose
magnesium stearate
stearic acid
magnesium silicate
- Drug Class:
- Alkylating agents
- Pregnancy Category:
- D - Positive evidence of risk
- CSA Schedule:
- N - Not a controlled drug
- Manufacturer:
- Bristol-Myers Squibb
- National Drug Code (NDC):
- 00015-0504
Advertisement
More Cytoxan resources
- Cytoxan (Wolters Kluwer)
- Cytoxan Tablets (Wolters Kluwer)
- Cytoxan oral/injection (Cerner Multum)
- Cytoxan (Micromedex) - Includes Dosage Information
- Cytoxan (AHFS DI)
- Cytoxan (FDA)
Cytoxan is associated with the treatment of:
- Acute Lymphocytic Leukemia
- Acute Nonlymphocytic Leukemia
- Bladder Cancer
- Brain Tumor
- Breast Cancer
- Bullous Pemphigoid
- Cancer
- Cervical Cancer
- Chronic Lymphocytic Leukemia
- Chronic Myelogenous Leukemia
- Cogan's Syndrome
- Dermatomyositis
- Endometrial Cancer
- Ewing's Sarcoma
- Histiocytosis
- Hodgkin's Lymphoma
- IgA Nephropathy
- Multiple Myeloma
- Multiple Sclerosis
- Mycosis Fungoides
- Nephrotic Syndrome
- Neuroblastoma
- Non-Hodgkin's Lymphoma
- Non-Small Cell Lung Cancer
- Organ Transplant, Rejection Prophylaxis
- Osteosarcoma
- Ovarian Cancer
- Pemphigoid
- Pemphigus
- Prostate Cancer
- Rheumatoid Arthritis
- Small Cell Lung Cancer
- Systemic Lupus Erythematosus
- Systemic Sclerosis
- Testicular Cancer
- Wegener's Granulomatosus
- Wilms' Tumor
Search Again
